Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2001, we proposed to restore this balance using judicious doses of antiangiogenic agents and suggested that this strategy would transiently give rise to tumour vessels with structural and functional phenotypes closer to those of the vessels of nonmalignant tissues — a state we referred to as ‘normalized’ (REF. 61)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“We also suggested that the use of other therapies during this ‘window of normalization’ (REF. 61) would result in better outcomes than if the same agents were given before or after this window.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [61]
In the citing paper
“Traditional angiogenesis inhibitors mainly block VEGF signaling and prune rather than eradicate tumor vessels.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [78]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“What mechanisms are responsible for this normalization? How can we exploit them? This knowledge will affect the treatment not only of cancer but also of other diseases characterized by abnormal vasculature—such as hemangiomas, arteriovenous malformations, diabetic retinopathy and macular degeneration—for which anti-an…”
BackgroundSelf-citationGenes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Self-citationLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Self-citationBaish, J. W., & Jain, R. K. (2000) · PubMed · Cited by 714
Self-citationThe next frontier of molecular medicine: Delivery of therapeutics
Jain, R. K. (1998) · Nature Medicine · doi:10.1038/nm0698-655 · Cited by 407
Self-citation
Research works printed but not linked: 6
- Folkman, J. in Harrison's Textbook of Internal Medicine, 15th ed. (eds Braunwald, E. et al.) 517–530 (McGraw-Hill, New York, 2001).
- Kozin, S.V. et al. VEGF receptor-2 blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61, 39–44 (2001).
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1α→HRE→VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Research 60, 6248–6252 (2000).
- Kadambi, A. et al. Vascular endothelial growth factor (VEGF)–C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res. 61, 2404–2408 (2001).
- Lee, C.G. et al. Anti-VEGF treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60, 5565–5570 (2000).
- Hansen-Algenstaedt, N. et al. Tumor oxygenation during VEGFR-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556–4560 (2000).
Cited by
Items 301–400 of 1,004
Tsukihara, H., Nakagawa, F., Sakamoto, K., Ishida, K., Tanaka, N., Okabe, H., Uchida, J., Matsuo, K., & Takechi, T. (2015) · Oncology Reports · doi:10.3892/or.2015.3876 · Cited by 109
Wang, Y., Chen, H., Liu, Y., Wu, J., Zhou, P., Wang, Y., Li, R., Yang, X., & Zhang, N. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.05.081 · Cited by 120
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Reynolds, A. R. (2010) · Dose-Response · doi:10.2203/dose-response.09-049.reynolds · Cited by 133
di Tomaso, E., Capen, D. E., Haskell, A., Hart, J., Logie, J. J., Jain, R. K., McDonald, D. M., Jones, R. C., & Munn, L. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4552 · Cited by 132
Self-citationLaurie, S. A., Gauthier, I. C., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E. X., Goss, G. D., Powers, J., Walsh, W., Tu, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4741 · Cited by 119
The blood brain barrier in Alzheimer’s disease
Chakraborty, A., de Wit, N. M., van der Flier, W. M., & de Vries, H. E. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.008 · Cited by 118
Solomon, B., Hagekyriakou, J., Trivett, M. K., Stacker, S. A., McArthur, G. A., & Cullinane, C. M. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)04357-2 · Cited by 118
Goel, S., Gupta, N., Walcott, B. P., Snuderl, M., Kesler, C. T., Kirkpatrick, N. D., Heishi, T., Huang, Y., Martin, J. D., Ager, E., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt164 · Cited by 117
Self-citationJain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0979 · Cited by 117
Self-citationArgiris, A. E., Karamouzis, M. V., Gooding, W. E., Branstetter, B. F., Zhong, S., Raez, L. E., Savvides, P. S., & Romkes, M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3591 · Cited by 117
Li, W., Zhao, X., Du, B., Li, X., Liu, S., Yang, X.-Y., Ding, H., Yang, W., Pan, F., Wu, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30619 · Cited by 116
Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Uribesalgo, I., Hoffmann, D., Zhang, Y., Kavirayani, A., Lazovic, J., Berta, J., Novatchkova, M., Pai, T., Wimmer, R. A., László, V., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809266 · Cited by 114
Stoll, B. R., Migliorini, C., Kadambi, A., Munn, L. L., & Jain, R. K. (2003) · Blood · doi:10.1182/blood-2003-02-0365 · Cited by 120
Self-citationRole of Macrophage Polarization in Tumor Angiogenesis and Vessel Normalization
Chen, P., & Bonaldo, P. (2013) · International review of cytology · doi:10.1016/b978-0-12-407704-1.00001-4 · Cited by 127
Goedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
Ultrasound in tumor immunotherapy: Current status and future developments
Ho, Y.-J., Li, J.-P., Fan, C., Liu, H.-L., & Yeh, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.023 · Cited by 119
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
Lemon, C. M., Karnas, E., Han, X., Bruns†, O. T., Kempa, T. J., Fukumura, D., Bawendi, M. G., Jain, R. K., Duda, D. G., & Nocera, D. G. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b04765 · Cited by 119
Self-citationMagnetic resonance elastography (MRE) in cancer: Technique, analysis, and applications
Pepin, K. M., Ehman, R. L., & McGee, K. P. (2015) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2015.06.001 · Cited by 122
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 105
High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer
Vella, G., Guelfi, S., & Bergers, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736670 · Cited by 123
Arakelyan, L., Vainstein, V., & Agur, Z. (2002) · Angiogenesis · doi:10.1023/a:1023841921971 · Cited by 123
Tumor angiogenesis, from foe to friend
Rivera, L. B., & Bergers, G. (2015) · Science · doi:10.1126/science.aad0862 · Cited by 108
Targeting Tumor Perfusion and Oxygenation to Improve the Outcome of Anticancer Therapy1
Jordan, B. F., & Sonveaux, P. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00094 · Cited by 120
Wang, H., Agarwal, P., Zhao, S., Yu, J., Lu, X., & He, X. (2015) · Nature Communications · doi:10.1038/ncomms10081 · Cited by 113
RetractedHan, M. Y., Huang-Fu, M.-Y., Guo, W.-W., Guo, N., Chen, J., Liu, H.-N., Xie, Z., Lin, M., Wei, Q., & Gao, J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10098 · Cited by 115
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.06.09 · Cited by 125
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 112
Crosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 117
Cancer therapy and cardiovascular risk: focus on bevacizumab
Economopoulou, P., Kentepozidis, N. K., Kotsakis, A. P., & Kapiris, I. (2015) · Cancer Management and Research · doi:10.2147/cmar.s77400 · Cited by 117
Zhou, L., Zhao, J., Chen, Y., Zheng, Y., Li, J., Zhao, J., Zhang, J., Liu, Y., Liu, X., & Wang, S. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111243 · Cited by 111
Helmberger, M., Pienn, M., Urschler, M., Kullnig, P., Stollberger, R., Kovács, G., Olschewski, A., Olschewski, H., & Bálint, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087515 · Cited by 120
Manegold, P. C., Paringer, C., Kulka, U., Krimmel, K., Eichhorn, M., Wilkowski, R., Jauch, K., Guba, M. O., & Bruns, C. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0955 · Cited by 117
Pak, R. W., Hadjiabadi, D. H., Senarathna, J., Agarwal, S., Thakor, N. V., Pillai, J. J., & Pathak, A. P. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17707398 · Cited by 118
New Strategies in Cancer Nanomedicine
Tong, R., & Kohane, D. S. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103456 · Cited by 113
Liu, X.-Q., Song, W.-J., Sun, T.-M., Zhang, P.-Z., & Wang, J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100315q · Cited by 108
Padhani, A. R., & Khan, A. A. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0135-8 · Cited by 111
Tumor Endothelial Heterogeneity in Cancer Progression
Maishi, N., Annan, D. A., Kikuchi, H., Hida, Y., & Hida, K. (2019) · Cancers · doi:10.3390/cancers11101511 · Cited by 110
Tumor refractoriness to anti-VEGF therapy
Ribatti, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8694 · Cited by 112
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
Hur, J., Hyun, M., Lim, S., Lee, W., & Kim, D. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22198 · Cited by 109
Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics
Ferretti, S., Allegrini, P. R., Becquet, M. M., & McSheehy, P. M. J. (2009) · Neoplasia · doi:10.1593/neo.09554 · Cited by 106
“The hypothesis of Jain [23] predicted, and provided evidence, that pruning of the vasculature by antiangiogenics would lead to narrower vessels, with decreased density and permeability and thus a lower IFP with, in some cases, increased blood flow and oxygenation.”
BackgroundAntibody Positron Emission Tomography Imaging in Anticancer Drug Development
Lamberts, L. E., Williams, S. P., van Scheltinga, A. G. T. T., Hooge, M. N. L., Schröder, C. P., Gietema, J. A., Brouwers, A. H., & de Vries, E. G. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.8278 · Cited by 111
Liu, K., Zhang, X., Xu, W., Chen, J., Yu, J. Q., Gamble, J. R., & McCaughan, G. W. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.28 · Cited by 112
Metabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
Dhaliwal, A., & Zheng, G. (2019) · Theranostics · doi:10.7150/thno.37204 · Cited by 103
Strategies for Delivering Nanoparticles across Tumor Blood Vessels
Sheth, V. M., Wang, L., Bhattacharya, R., Mukherjee, P., & Wilhelm, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202007363 · Cited by 110
Antiangiogenic Therapies: Going beyond Their Limits
Moserle, L., Jiménez-Valerio, G., & Casanovas, O. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0199 · Cited by 102
Bevacizumab: overview of the literature
Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.13 · Cited by 100
Cao, Z., Shang, B., Zhang, G., Miele, L., Sarkar, F. H., Wang, Z. P., & Zhou, Q. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.08.001 · Cited by 109
TSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche
Yamamoto, M., Kikuchi, H., Ohta, M., Kawabata, T., Hiramatsu, Y., Kondo, K., Baba, M., Kamiya, K., Tanaka, T., Kitagawa, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1748 · Cited by 105
Two Steps Forward in the Treatment of Colorectal Cancer
Mayer, R. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048098 · Cited by 116
Chen, Q., Xu, L., Chen, J., Yang, Z., Liang, C., Yang, Y., & Liu, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.021 · Cited by 104
Tian, Y., Zhai, X., Han, A., Zhu, H., & Yu, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0753-2 · Cited by 108
Strieth, S., Eichhorn, M., Sauer, B., Schulze, B. G., Teifel, M., Michaelis, U., & Dellian, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20083 · Cited by 104
Extracellular Matrix Proteins and Tumor Angiogenesis
Campbell, N. E., Kellenberger, L., Greenaway, J., Moorehead, R. A., Linnerth-Petrik, N. M., & Petrik, J. (2010) · Journal of Oncology · doi:10.1155/2010/586905 · Cited by 101
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
Rak, J. W., Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · PubMed · Cited by 113
Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer
Savai, R., Langheinrich, A. C., SCHERMULY, R. T., Pullamsetti, S. S., Dumitrascu, R., Traupe, H., Rau, W. S., Seeger, W., Grimminger, F., & Banat, G. A. (2009) · Neoplasia · doi:10.1593/neo.81036 · Cited by 103
Liu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 102
Nitric oxide delivery to cancer: Why and how?
Sonveaux, P., Jordan, B. F., Gallez, B., & Féron, O. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.12.018 · Cited by 113
Supramolecular Nitric Oxide Depot for Hypoxic Tumor Vessel Normalization and Radiosensitization
Yang, C., Mu, G., Zhang, Y., Gao, Y., Zhang, W., Liu, J., Zhang, W., Li, P., Yang, L., Yang, Z., et al. (2022) · Advanced Materials · doi:10.1002/adma.202202625 · Cited by 104
Linking tumour angiogenesis and tumour immunity
Kabir, A. U., Subramanian, M., Kwon, Y., & Choi, K. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01211-z · Cited by 111
Nakahara, T., Norberg, S. M., Shalinsky, D. R., Hu-Lowe, D. D., & McDonald, D. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0923 · Cited by 102
Zhang, J. C., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., & Ouyang, L. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.016 · Cited by 106
A Computational Model for Predicting Nanoparticle Accumulation in Tumor Vasculature
Frieboes, H. B., Wu, M., Lowengrub, J., Decuzzi, P., & Cristini, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056876 · Cited by 100
Huang, Y., Snuderl, M., & Jain, R. K. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.005 · Cited by 100
Self-citationLiu, S.-Y., Chang, L., Pan, L.-F., Hung, Y.-J., Lee, C.-H., & Shieh, Y. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2007.02.007 · Cited by 110
VEGF in Tumor Progression and Targeted Therapy
Chekhonin, V. P., Shein, S. A., Korchagina, A. A., & Gurina, O. I. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990074 · Cited by 103
Qian, C., Liu, C., Liu, W., Zhou, R., & Zhao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291530 · Cited by 103
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer
Wright, J. D., Viviano, D. L., Powell, M. A., Gibb, R. K., Mutch, D. G., Grigsby, P. W., & Rader, J. S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.023 · Cited by 100
New Technologies and Directed Agents for Applications of Cancer Imaging
Atri, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6159 · Cited by 108
Interleukin-22 promotes tumor angiogenesis
Protopsaltis, N. J., Liang, W. P., Nudleman, E., & Ferrara, N. (2018) · Angiogenesis · doi:10.1007/s10456-018-9658-x · Cited by 103
An analysis of radiation necrosis of the central nervous system treated with bevacizumab
Tye, K. E., Engelhard, H. H., Slavin, K. V., Nicholas, M. K., Chmura, S. J., Kwok, Y., Ho, D. S., Weichselbaum, R. R., & Koshy, M. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1391-8 · Cited by 99
Current approach in the treatment of hepatocellular carcinoma
Rossi, L., Zoratto, F., Papa, A., Iodice, F., Minozzi, M., Frati, L., & Tomao, S. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i9.348 · Cited by 106
Bevacizumab Suppression of Establishment of Micrometastases in Experimental Ocular Melanoma
Yang, H., Jager, M. J., & Grossniklaus, H. E. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4755 · Cited by 96
Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas
Jansen, M., Hamer, P. C. D. W., Witmer, A. N., Troost, D., & Noorden, C. J. F. V. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.03.001 · Cited by 108
Szpunar, M. J., Belcher, E. K., Dawes, R. P., & Madden, K. S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.12.014 · Cited by 90
Tsang, C. M., Cheung, K. C.-P., Cheung, Y. C., Man, K., Lui, V. W. Y., Tsao, S. W., & Feng, Y. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.004 · Cited by 98
Jaffe, G. J., Eliott, D., Wells, J. A., Prenner, J. L., Papp, A., & Patel, S. C. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.004 · Cited by 100
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
Tumor Engineering: The Other Face of Tissue Engineering
Ghajar, C. M., & Bissell, M. J. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0135 · Cited by 96
Plaque neovascularization: defense mechanisms, betrayal, or a war in progress
Moreno, P., Purushothaman, M., & Purushothaman, K. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06497.x · Cited by 107
Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms
Miletić, H., Niclou, S. P., Johansson, M., & Bjerkvig, R. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902806444 · Cited by 103
Sinek, J. P., Frieboes, H. B., Zheng, X., & Vittorio Cristini, C. (2004) · Biomedical Microdevices · doi:10.1023/b:bmmd.0000048562.29657.64 · Cited by 95
Fan, Y., Potdar, A. A., Gong, Y., Eswarappa, S. M., Donnola, S., Lathia, J. D., Hambardzumyan, D., Rich, J. N., & Fox, P. L. (2014) · Nature Cell Biology · doi:10.1038/ncb2954 · Cited by 92
A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology
Acker, T., & Plate, K. H. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0355-1 · Cited by 78
Bhattacharya, A., Seshadri, M., Oven, S. D., Tóth, K., Vaughan, M. M., & Rustum, Y. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0212 · Cited by 93
Beal, K. P., Abrey, L. E., & Gutin, P. H. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-2 · Cited by 105
Antiangiogenic drugs in ovarian cancer
Kumaran, G., Jayson, G. C., & Clamp, A. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604767 · Cited by 99
Molecular targeted therapy for hepatocellular carcinoma
Thomas, M. B. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-008-2252-z · Cited by 98
Contribution of VEGF and PEDF to choroidal angiogenesis: A need for balanced expressions
Tong, J., & Yao, Y. (2006) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2005.11.013 · Cited by 94
Digital optical tomography system for dynamic breast imaging
Flexman, M. L., Khalil, M. A., Kim, H. K., Fong, C. J., Hielscher, A. H., Abdi, R. A., Barbour, R. L., Desperito, E., & Hershman, D. L. (2011) · Journal of Biomedical Optics · doi:10.1117/1.3599955 · Cited by 94
Bevacizumab-Induced Hypertension: Pathogenesis and Management
Syrigos, K., Karapanagiotou, E. M., Boura, P., Manegold, C., & Harrington, K. J. (2011) · BioDrugs · doi:10.2165/11590180-000000000-00000 · Cited by 108
Cascone, T., Xu, L., Lin, H. Y., Liu, W., Tran, H. T., Liu, Y., Howells, K., Haddad, V., Hanrahan, E. O., Nilsson, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3216 · Cited by 97
The Immunobiology of Kidney Cancer
Drake, C. G., & Stein, M. N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2648 · Cited by 104
Matsumoto, S., Yasui, H., Batra, S., Kinoshita, Y., Bernardo, M., Munasinghe, J., Utsumi, H., Choudhuri, R., Devasahayam, N., Subramanian, S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908447106 · Cited by 93
Granata, V., Fusco, R., Catalano, O., Filice, S., Amato, D. M., Nasti, G., Avallone, A., Izzo, F., & Petrillo, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142876 · Cited by 92
Molecularly targeted therapies for recurrent glioblastoma: current and future targets
Lau, D., Magill, S. T., & Aghi, M. K. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14519 · Cited by 97
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents
DeBono, A., Capuano, B., & Scammells, P. J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501180v · Cited by 95
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
Yang, F., Lee, G., & Fan, Y. (2024) · Angiogenesis · doi:10.1007/s10456-024-09913-z · Cited by 94
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Medicine
- Published
- 2001-09
- Volume
- 7
- Issue
- 9
- Pages
- 987-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1603230122
- Cited by
- 2,184
- References
- 26
- Citations by year
- 2026: 58 · 2025: 65 · 2024: 61 · 2023: 88 · 2022: 97 · 2021: 91 · 2020: 93 · 2019: 91 · 2018: 69 · 2017: 94 · 2016: 82 · 2015: 106 · 2014: 94 · 2013: 101 · 2012: 124
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, tumor vasculature normalization, solid tumors, cancer prevention, combination therapy, drug delivery to tumors, tumor vasculature
- MeSH terms
- Blood Vessels, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.